Linezolid Hikma

Linezolid, the active ingredient in Linezolid Hikma, is an oxazolidinone presented as an intravenous solution for intravenous use. It treats complicated skin and soft tissue infections, community‑acquired and nosocomial pneumonia, as well as infections caused by methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE) in adult patients.

GNH USA supplies Linezolid Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Linezolid is an oxazolidinone antibiotic used to treat serious bacterial infections.

- Complicated skin and soft tissue infections: provides clinical cure against Gram‑positive pathogens, including MRSA. - Community‑acquired and nosocomial pneumonia: eradicates causative bacteria and improves respiratory outcomes. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: offers bacteriostatic activity against MRSA strains. - Vancomycin‑resistant Enterococcus (VRE) infections: serves as an alternative therapeutic option for VRE infections.

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, usually self‑limiting. - Headache: transient cranial discomfort. - Thrombocytopenia: mild reduction in platelet count.

Serious or Rare Side Effects: - Myelosuppression: significant decrease in blood cell lines, requiring monitoring. - Peripheral neuropathy: nerve damage presenting as tingling or numbness. - Lactic acidosis: rare metabolic disturbance with high mortality. - Serotonin syndrome: risk when combined with serotonergic agents.

When using Linezolid, several safety considerations should be observed.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: use with caution; periodic liver‑function tests are recommended. - Hematologic monitoring: perform regular complete blood counts due to risk of thrombocytopenia. - Concomitant serotonergic drugs: avoid or closely monitor for serotonin syndrome. - Pregnancy and lactation: safety not established; prescribe only if benefit outweighs potential risk. - Store at ambient temperature: keep in original container, protect from light and moisture.

Linezolid interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): increased serotonin toxicity. - Rifampin: may reduce linezolid plasma concentrations. - Erythromycin: may increase linezolid levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR; monitor coagulation parameters. - Anticonvulsants (e.g., carbamazepine): may affect metabolism; observe therapeutic response. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive risk of thrombocytopenia.